viewDestiny Pharma PLC

Destiny Pharma PLC - Notice of Results

RNS Number : 5360Y
Destiny Pharma PLC
10 September 2020

Destiny Pharma plc

("Destiny Pharma" or "the Company") 


Notice of Interim Results


Brighton, United Kingdom - 10 September 2020 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), will announce its financial results for the six months ended 30 June 2020 on Thursday, 17 September 2020. 

A webcast for analysts will take place at 09:30am BST.


For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[email protected] 

+44 (0)1273 704 440


Optimum Strategic Communications

Mary Clark, Shabnam Bashir, Manel Mateus

Tel: +44 (0) 203 174 1789

Email: [email protected] 


finnCap Ltd (Nominated Advisor Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

+44 (0)20 7220 0500


WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

+44 (0) 203 705 9330


About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines from its XF Platform that represent a new approach to the treatment of infectious disease. The company's lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post-surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic‑resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: Destiny Pharma PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Destiny Pharma awaits key inflection point mid--2020 in its antimicrobial...

Destiny Pharma (LON:DEST) CEO Neil Clark spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The UK-based, clinical phase biotechnology company is focused on preventing post-surgical infection in a Phase 2b clinical trial with its lead asset. According to its website, Destiny is...

on 01/15/2020

3 min read